Raphael Zidovetzki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7229712/publications.pdf

Version: 2024-02-01

1039406 1372195 1,362 11 9 10 citations g-index h-index papers 11 11 11 2949 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Use of cyclodextrins to manipulate plasma membrane cholesterol content: Evidence, misconceptions and control strategies. Biochimica Et Biophysica Acta - Biomembranes, 2007, 1768, 1311-1324.	1.4	913
2	Lupus Nephritis Susceptibility Loci in Women with Systemic Lupus Erythematosus. Journal of the American Society of Nephrology: JASN, 2014, 25, 2859-2870.	3.0	117
3	Systems protobiology: origin of life in lipid catalytic networks. Journal of the Royal Society Interface, 2018, 15, 20180159.	1.5	102
4	Nicotine Increases Plasminogen Activator Inhibitor-1 Production by Human Brain Endothelial Cells via Protein Kinase C–Associated Pathway. Stroke, 1999, 30, 651-655.	1.0	96
5	Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4 ⁺ T-lymphocyte counts. CNS Oncology, 2018, 7, CNS22.	1.2	49
6	Systemic Lupus Erythematosus-associated Neutrophil Cytosolic Factor 2 Mutation Affects the Structure of NADPH Oxidase Complex. Journal of Biological Chemistry, 2015, 290, 12595-12602.	1.6	28
7	Transmembrane domains in the functions of Fc receptors. Biophysical Chemistry, 2002, 100, 555-575.	1.5	26
8	Therapeutic Immunization against Glioblastoma. International Journal of Molecular Sciences, 2018, 19, 2540.	1.8	14
9	Replication of simulated prebiotic amphiphile vesicles controlled by experimental lipid physicochemical properties. Physical Biology, 2011, 8, 066001.	0.8	9
10	Replication of Simulated Prebiotic Amphiphilic Vesicles in a Finite Environment Exhibits Complex Behavior That Includes High Progeny Variability and Competition. Astrobiology, 2018, 18, 419-430.	1.5	8
11	ATIM-28. PHASE 2 STUDY OF ERC1671 PLUS BEVACIZUMAB VS BEVACIZUMAB PLUS PLACEBO IN RECURRENT GBM INTERIM RESULTS AND CORRELATIONS WITH CD4+ T LYMPHOCYTE COUNTS. Neuro-Oncology, 2018, 20, vi7-vi7.	0.6	0